Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)

Recruiting

Phase 1

Phase 2

Bortezomib & CPX-351Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)

Sponsor:

Masonic Cancer Center, University of Minnesota

Code:

NCT07008638

Conditions

Acute Myeloid Leukemia

TP53

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Bortezomib

CPX-351

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-01-18. This information was provided to ClinicalTrials.gov by Masonic Cancer Center, University of Minnesota on 2025-07-09.